| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 06/04/2013 | US8455622 Variant target binding agents and uses thereof |
| 06/04/2013 | US8455447 Modified therapeutic agents |
| 06/04/2013 | US8455445 Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders |
| 06/04/2013 | US8455249 Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo |
| 06/04/2013 | US8455219 Mammalian expression vectors and uses thereof |
| 06/04/2013 | US8455215 Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
| 06/04/2013 | US8455212 Assays for human NT-pro B-type natriuretic peptide, human pro B-type natriuretic peptide and human B-type natriuretic peptide |
| 06/04/2013 | US8455206 Human lysosomal protein and methods of its use |
| 06/04/2013 | US8454976 Recombinant toxin fragments |
| 06/04/2013 | US8454965 Method for the treatment of multiple sclerosis |
| 06/04/2013 | US8454963 Tissue targeted complement modulators |
| 06/04/2013 | US8454962 Alpha-4-beta-7 heterodimer specific antagonist antibody |
| 06/04/2013 | US8454961 Alpha-4-beta-7 heterodimer specific antagonist antibody |
| 06/04/2013 | US8454960 Multispecific antibody targeting and multivalency through modular recognition domains |
| 06/04/2013 | US8454958 Methods for detecting and inhibiting angiogenesis |
| 06/04/2013 | US8454953 Methods for reducing allergies caused by environmental allergens |
| 06/04/2013 | US8454952 Augmentation of endothelial thromboresistance |
| 06/04/2013 | CA2602849C Doxorubicin immunoassay |
| 06/04/2013 | CA2554054C Mixtures of binding proteins |
| 06/04/2013 | CA2541709C Anti-pecam therapy for metastasis suppression |
| 06/04/2013 | CA2499926C Antibody against von willebrand factor cleaving enzyme and assay system using the same |
| 06/04/2013 | CA2405063C Subtilisin variants |
| 06/04/2013 | CA2228667C Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers |
| 06/02/2013 | CA2772180A1 Anti-npy and pyy antibodies and uses thereof |
| 05/30/2013 | WO2013078378A1 Methods of treatment using an antibody against interferon gamma |
| 05/30/2013 | WO2013078377A1 Anti-cd98 antibodies and methods of use thereof |
| 05/30/2013 | WO2013078375A2 Administration of alpha4beta7 hetero-dimer-specific antibody |
| 05/30/2013 | WO2013078223A1 Anti-factor h binding protein antibodies and methods of use thereof |
| 05/30/2013 | WO2013078191A1 Binding molecules specific for her3 and uses thereof |
| 05/30/2013 | WO2013078170A1 Purification of anti-c-met antibodies |
| 05/30/2013 | WO2013078089A1 Anti-tim-1 antibodies and uses thereof |
| 05/30/2013 | WO2013077907A1 Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
| 05/30/2013 | WO2013077458A1 Anti-human trop-2 antibody exhibiting antitumor activity in vivo |
| 05/30/2013 | WO2013077332A1 Method for detecting matrix metalloproteinase-3 by latex agglutination method |
| 05/30/2013 | WO2013077186A1 Activity modulator, medicinal agent comprising same, use of cd300a gene-deficient mouse, and anti-cd300a antibody |
| 05/30/2013 | WO2013076304A1 Monoclonal antibody for the detection of snap/clip tag |
| 05/30/2013 | WO2013076194A1 Methods and pharmaceutical compositions for reducing airway hyperresponse |
| 05/30/2013 | WO2013076186A1 Anti-fgfr2 antibodies and uses thereof |
| 05/30/2013 | WO2013076183A1 Combination therapy using anti - cd20 antibody and human il-15 |
| 05/30/2013 | WO2013076139A1 Cd40l expressing mammalian cells and their use |
| 05/30/2013 | WO2013075630A1 Nano particles of nucleic acid and preparation process and use thereof, and three-head single chain nucleic acid unit |
| 05/30/2013 | WO2013075382A1 Anti human her2 monoclonal antibody |
| 05/30/2013 | WO2013075237A1 Mutations of histone proteins associated with proliferative disorders |
| 05/30/2013 | WO2013052926A3 Methods and compositions for single chain variable region enox2 antibodies for cancer detection and diagnosis |
| 05/30/2013 | WO2013052772A3 Anti-human sema4a antibodies useful to treat disease |
| 05/30/2013 | WO2013045934A3 Compositions comprising agents that inhibit neuropilin and tolloid like 2 |
| 05/30/2013 | WO2013043933A3 Cd27l antigen binding proteins |
| 05/30/2013 | WO2013041730A8 Serum half-life extension using immunoglobulin binding domains |
| 05/30/2013 | WO2013014405A3 Methods of inhibiting inflammation comprising inhibiting cd63 |
| 05/30/2013 | WO2011140114A3 Anti-glucosaminidase passive immunization for staphylococcus aureus infections |
| 05/30/2013 | US20130137855 Humanized anti-interleukin 3 receptor alpha chain antibodies |
| 05/30/2013 | US20130137763 Fused cyclooctyne compounds and their use in metal-free click reactions |
| 05/30/2013 | US20130137758 Akt activity specifically inhibiting polypeptide |
| 05/30/2013 | US20130137659 Anticancer derivatives, preparation thereof and therapeutic use thereof |
| 05/30/2013 | US20130137603 Newly identified colon cancer marker and diagnostic kit using the same |
| 05/30/2013 | US20130137118 Integrin heterodimer and a subunit thereof |
| 05/30/2013 | US20130137106 Tumor Marker and Methods of Use Thereof |
| 05/30/2013 | US20130136756 Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
| 05/30/2013 | US20130136751 Methods, Compositions and Kits Relating to Chitnases and Chitnase-Like Molecules and Inflammation Disease |
| 05/30/2013 | US20130136750 Antibodies which bind factor viii |
| 05/30/2013 | US20130136749 Human CTLA-4 Antibodies And Their Uses |
| 05/30/2013 | US20130136748 Biological materials related to her3 |
| 05/30/2013 | US20130136747 Anti-amyloid beta antibodies and their use |
| 05/30/2013 | US20130136745 Soluble endoglin and uses thereof |
| 05/30/2013 | US20130136743 Novel mutated humanized 12g4 antibodies and the fragments thereof against the human anti-mullerian hormone receptor type ii |
| 05/30/2013 | US20130136736 Single Domain VHH Antibodies Against Von Willebrand Factor |
| 05/30/2013 | US20130136735 HUMANIZED ANTIBODIES TO iNKT |
| 05/30/2013 | US20130136734 ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND RELATED THERAPIES |
| 05/30/2013 | US20130136718 Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities |
| 05/30/2013 | CA2856873A1 Anti-cd98 antibodies and methods of use thereof |
| 05/30/2013 | CA2856866A1 Administration of alpha4beta7 hetero-dimer-specific antibody |
| 05/30/2013 | CA2856325A1 Anti-fgfr2 antibodies and uses thereof |
| 05/30/2013 | CA2856297A1 Binding molecules specific for her3 and uses thereof |
| 05/30/2013 | CA2856258A1 Monoclonal antibodies specific for the m2-1 antigen of respiratory syncytial virus (rsv) |
| 05/30/2013 | CA2856252A1 Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles |
| 05/30/2013 | CA2855699A1 Anti-human trop-2 antibody having an antitumor activity in vivo |
| 05/30/2013 | CA2854921A1 Methods of treatment using an antibody against interferon gamma |
| 05/30/2013 | CA2854857A1 Monoclonal antibody for the detection of snap/clip tag |
| 05/30/2013 | CA2854477A1 Purification of anti-c-met antibodies |
| 05/30/2013 | CA2854255A1 Mutations of histone proteins associated with proliferative disorders |
| 05/30/2013 | CA2854244A1 Methods and pharmaceutical compositions for reducing airway hyperresponse |
| 05/30/2013 | CA2851210A1 Combination therapy using anti-cd20 antibody and human il-15 |
| 05/30/2013 | CA2850694A1 Cd40l expressing mammalian cells and their use |
| 05/29/2013 | EP2597151A2 Recombinant microorganisms, methods for preparing vaccine strains, antigens, and vector vaccine compositions of same, uses thereof, and related antibodies, diagnostic kit, and treatment and/or prophylactic methods |
| 05/29/2013 | EP2597104A1 Antibodies against human TWEAK and uses thereof |
| 05/29/2013 | EP2597102A1 A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17 |
| 05/29/2013 | EP2596365A2 Monoclonal antibodies against pcbp-1 antigens, and uses therefor |
| 05/29/2013 | EP2596114A2 Domain insertion immunoglobulin |
| 05/29/2013 | EP2596027A1 Novel antigen binding proteins |
| 05/29/2013 | EP2596026A1 Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
| 05/29/2013 | EP2596025A1 Methods for cancer management targeting co-029 |
| 05/29/2013 | EP2596024A1 Anti-cd19 antibody having adcc function with improved glycosylation profile |
| 05/29/2013 | EP2596023A2 Compositions and methods featuring il-6 and il-21 antagonists |
| 05/29/2013 | EP2596022A1 Anti-il-23 heterodimer specific antibodies |
| 05/29/2013 | EP2596021A2 A method of treating alzheimer's disease |
| 05/29/2013 | EP2596020A2 Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy |
| 05/29/2013 | EP2596019A2 A method of treating attention deficit hyperactivity disorder |
| 05/29/2013 | EP2596018A2 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
| 05/29/2013 | EP2596017A1 Cross-protective pathogen protection, methods and compositions thereof |
| 05/29/2013 | EP2596016A1 Intracellular immunity |